Type 2 Diabetes Mellitus Completed Phase 4 Trials for Insulin glargine (DB00047)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02455076Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 DiabetesTreatment
NCT03013985Glargine U300 Hospital TrialTreatment
NCT02004366Linagliptin Inpatient TrialTreatment
NCT00979628Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)Treatment
NCT01524705FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)Treatment
NCT00736515Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 DiabetesTreatment
NCT02325960A Comparison of Exenatide and Insulin GlargineTreatment
NCT00191178Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 DiabetesTreatment
NCT00596687Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General SurgeryTreatment
NCT00609856Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 DiabetesTreatment
NCT00699686Endothelial Effects of Basal Insulin: Detemir Versus GlargineTreatment
NCT00857870Insulin Glargine First Line vs Metformin in Type 2 Diabetic SubjectsTreatment
NCT00862875Levemir-Body Composition and Energy MetabolismTreatment
NCT00911625Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal InsufficiencyTreatment
NCT01249677Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 DiabetesTreatment
NCT01845831Sitagliptin Therapy in Hospitalized Patients With Type 2 DiabetesTreatment
NCT02545842Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)Treatment
NCT02561130Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With ForxigaTreatment
NCT02954692A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyTreatment
NCT01378117Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 DiabetesTreatment
NCT00311818Insulin Glargine in Type 2 Diabetes MellitusTreatment
NCT00358124Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination TherapyTreatment
NCT00467649A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 DiabetesTreatment
NCT00548808A Study for Type 2 Diabetic PatientsTreatment
NCT00562172Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)Treatment
NCT00641407Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 DiabetesTreatment
NCT00686712Insulin Glargine at Bedtime or in AM Versus NPHTreatment
NCT00708578Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)Treatment
NCT00766857Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart FailureTreatment
NCT00913367Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes MellitusTreatment
NCT01181674Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)Treatment
NCT01269996JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic PatientsTreatment
NCT01461577Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) FailureTreatment
NCT01832935Cost Effectiveness of Glargine Insulin Versus NPH InsulinBasic Science
NCT02200991Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin GlargineTreatment
NCT02680457Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes MellitusTreatment
NCT00354939Insulin Analogue With Continuous Glucose Monitoring System (CGMS) MeasurementTreatment
NCT02836704Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)Treatment
NCT02451137A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)Treatment
NCT02453685A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic PatientsTreatment
NCT02606357Treatment of Type 2 Diabetes With Long Acting Basal Insulin in JordanTreatment
NCT00418522This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes MellitusTreatment
NCT02738151Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistTreatment
NCT02967224A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating InsulinTreatment
NCT02967211A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal InsulinTreatment
NCT00909480Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 DiabetesTreatment
NCT00469092Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 DiabetesTreatment
NCT00423215LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
NCT00488527DOMME Dose Optimization Multicentric Mexican EvaluationTreatment
NCT00367445A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and LantusTreatment
NCT00360698Insulin Glulisine in Type 2 Diabetic PatientsTreatment
NCT00384215Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or MetforminTreatment
NCT00384085Insulin Glargine All to Target TrialTreatment
NCT00399724A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusTreatment
NCT00405418Lantus Versus Levemir Treat-To-TargetTreatment
NCT00391027A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®Treatment
NCT00377858Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)Treatment
NCT00965549Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes PatientsTreatment
NCT00552370Glycemic Optimization Treatment StudyTreatment
NCT00553020Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 DiabetesTreatment
NCT01203111Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering DrugsTreatment
NCT01226043Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes MellitusTreatment
NCT00693771Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed InsulinTreatment
NCT00659477Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)Treatment
NCT01123980Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin TreatmentTreatment
NCT00619697Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 DiabetesTreatment
NCT01013571Self Titration With Apidra to Reach Target Study (START)Treatment
NCT01234597Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a DayTreatment
NCT00184626Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.Treatment
NCT02967237Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin TreatmentTreatment
NCT01169818Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes MellitusTreatment
NCT00751114Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive PatientsTreatment
NCT01127269Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 DiabetesTreatment
NCT01175811A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes MellitusTreatment
NCT02027753Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor TherapyTreatment
NCT01175824Comparison of the Efficacy and Safety of Two Insulin Intensification StrategiesTreatment
NCT00279201The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)Treatment
NCT00335465Lantus Effect on Myocardial Glucose Metabolism in T2Treatment
NCT00347100Insulin Glargine in Type 2 Diabetic PatientsTreatment
NCT00174824Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic PatientsTreatment
NCT00174681Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 DiabetesTreatment
NCT00191464Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 DiabetesTreatment
NCT00191282Hyperglycemia and Cardiovascular Outcomes With Type 2 DiabetesTreatment
NCT00258804Insulin Glargine During and After the Period of Fasting in RamadanTreatment
NCT00268645Insulin Glargine in Type 2 DiabetesTreatment
NCT01121835Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative StudyTreatment
NCT00664534Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light BreakfastTreatment
NCT01122979Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.Treatment
NCT00701831Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic ControlTreatment
NCT01117350Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents FailureTreatment
NCT01212913Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)Treatment
NCT00518427Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline GlargineTreatment